RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 267 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2024. The put-call ratio across all filers is 2.47 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,769,225 | – | 769,230 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $103,744,510 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $39,392,876 | 55.14% |
| Data Collective IV GP, LLC | 5,941,120 | $59,232,966 | 51.36% |
| NVIDIA CORP | 7,706,363 | $76,832,439 | 23.09% |
| MIC Capital Management UK LLP | 8,451,758 | $84,264,027 | 16.00% |
| ARK Investment Management | 24,587,561 | $245,137,979 | 1.70% |
| Nikko Asset Management Americas, Inc. | 10,362,803 | $103,109,890 | 1.02% |
| Lingotto Investment Management LLP | 2,175,077 | $21,685,518 | 0.91% |
| Institute for Wealth Management, LLC. | 581,149 | $5,794,055 | 0.75% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,800,469 | $17,950,676 | 0.72% |